Ardelyx (ARDX) vs ArriVent BioPharma (AVBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ArriVent BioPharma (AVBP) has outperformed Ardelyx (ARDX) over the past year, losing 19.7% versus a loss of 35.4%. Ardelyx is the larger company by market cap ($844.3 million vs $823.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | AVBP |
|---|---|---|
| Share price | $3.27 | $16.71 |
| Market cap | $844.27M | $823.93M |
| 1-day change | +0.31% | -1.07% |
| YTD return | -43.91% | -16.95% |
| 1-year return | -35.38% | -19.74% |
| 5-year return | +202.78% | — |
| Forward P/E | 11.26 | — |
| EPS (TTM) | $-0.23 | $-3.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $35.83 |
| 52-week low | $3.18 | $11.36 |
| Distance from 52-week high | -61.07% | -53.36% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +294.50% | +82.53% |
| Average volume | 4.17M | 908.55K |
| Shares outstanding | 258.19M | 49.31M |
| Employees | 489 | 77 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVBP has outperformed ARDX by 15.6 percentage points over the past year.
- The two companies sit in different sectors: Ardelyx in Healthcare and ArriVent BioPharma in Health Care.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Healthcare · Biotechnology · 489 employees
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 77 employees
ARDX vs AVBP FAQ
Which is bigger, Ardelyx or ArriVent BioPharma?
Ardelyx (ARDX) is larger, with a market capitalization of $844.27M compared with $823.93M for ArriVent BioPharma (AVBP).
Which stock has performed better over the past year, ARDX or AVBP?
AVBP returned -19.74% over the past 12 months, compared with -35.38% for ARDX (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and ArriVent BioPharma in the same industry?
No. Ardelyx is in the Healthcare sector, while ArriVent BioPharma is in Health Care.